Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31026422 | 1.00 | NNMT (0.44) | NNMTCYP2A6MKNK1MKNK2KDM4E | |
| SCHEMBL21801745 | 0.85 | CA1 (0.41) | NNMTCYP2A6KDM4EMAPTLMNA | |
| SCHEMBL30501667 | 0.81 | MAPT (0.49) | MAPT | |
| SCHEMBL17766744 | 0.80 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL15563753 | 0.80 | KMT2A (0.42) | NNMTHSD17B1HSD17B2MAPTLMNA | |
| SCHEMBL3816388 | 0.79 | NNMT (0.48) | NNMTCYP2A6MKNK1MKNK2KDM4E | |
| SCHEMBL29525223 | 0.79 | NNMT (0.48) | NNMTCYP2A6MKNK1MKNK2KDM4E | |
| SCHEMBL38660384 | 0.78 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL2891613 | 0.78 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL5424020 | 0.76 | KMT2A (0.42) | CHRNB2CHRNA4MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412669-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
| CN-105209467-B | Imidazopyrrolidinone derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-104854090-B | Heteroaryl derivative and its purposes | 雅各布斯制药公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-106029661-B | Pyrazolo [1,5-A ] pyridine derivatives and methods of use thereof | 亚尼塔公司 | 2017-11-03 | — | — | CN | disclosed |
| EP-2896622-B1 | PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2017-05-03 | — | — | EP | disclosed |
| CN-106029661-A | Pyrazolo [1,5-A ] pyridine derivatives and methods of use thereof | 亚尼塔公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-102863432-B | CFTR conditioning agent | 沃泰克斯药物股份有限公司 | 2016-09-07 | — | — | CN | disclosed |
| CN-105693730-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | 西格诺药品有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-105693744-A | Substituted thiophene and pyrimidine compound and preparation method thereof | 北大方正集团有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-101600720-A | Phosphoinositide 3-kinase inhibitor compounds and using method | HOFFMANN LA ROCHE (CH) | 2009-12-09 | — | — | CN | disclosed |
| CN-101573360-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2009-11-04 | — | — | CN | disclosed |
| CN-101312966-A | Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands | ABBOTT LAB (US) | 2008-11-26 | — | — | CN | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
| CN-101277958-A | Naphthyridin derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-01 | — | — | CN | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| CN-1960969-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI (US) | 2007-05-09 | — | — | CN | disclosed |
| CN-1726205-A | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | NNMT 3060/4885CYP2A6 347/4885MKNK1 4792/4885 |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | NNMT 1128/4885CYP2A6 295/4885MKNK1 2374/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | NNMT 3060/4885CYP2A6 347/4885MKNK1 4792/4885 |
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | BRD3, BRD4, BRPF3 | NNMT 327/4885CYP2A6 2843/4885MKNK1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.